About
Reglagene develops an orally administered, low molecular weight, tubulin-targeting small molecule therapy that crosses the blood-brain barrier to treat brain cancers, demonstrating efficacy in preclinical animal studies where standard treatments fail.
Explore Reglagene's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.